# CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

> **NCT02189629** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 453 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** CD5789 (trifarotene)

## Key facts

- **NCT ID:** NCT02189629
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-23
- **Primary completion:** 2017-02-23
- **Final completion:** 2017-02-23
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02189629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02189629, "CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02189629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*